CD276 and adrenal cortex carcinoma: More importantly, the recurrence-related effects of CD276 were also apparent in both ACC subgroups of earlier (I/II, P = 0.002, Figure 4(b)) and advanced ENSAT (III/IV, P < 0.001, Figure 4(c)) stages.